An open letter to the Alzheimer’s disease community from Biogen Head of Research and Development, Alfred Sandrock, M.D., Ph.D
Statement from Head of Research and Development, Alfred Sandrock, M.D., Ph.D.:Biogen Inc. – On June 7, 2021, Aduhelm became the first approved treatment to address a defining pathology… read more.